ZZZe Zhou

Ze Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ze Zhou has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Amit Roshan

    Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, UK

    3 shared publications
  • Hui Zhao

    Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK

    2 shared publications
  • Nitzan Rosenfeld

    The Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK

    2 shared publications
  • Wendy N. Cooper

    Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK

    2 shared publications
  • Ahmad Miremadi

    Histopathology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

    1 shared publication
  • Alexander A. Azizi

    Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

    1 shared publication

Latest Publications

  • Open Access

    ctDNA predicts radiological response to immune checkpoint inhibition for patients with advanced oesophageal adenocarcinoma: a pilot interventional phase 2 study

    by Constanza Linossi, Alexander A. Azizi, Andrea Machin, Alimu Dayimu, Nikos Demiris, Helen White, Ahmad Miremadi, Maria O’DOnovan, Edmund Godfrey, Paulius D. Mennea, et al.

    Background: Second line treatments for advanced oesophageal adenocarcinoma (OAC) have limited efficacy, and biomarkers for early relapse are needed. We evaluated the use of a Next Generation Sequencing (NGS) based circulating tumour DNA (ctDNA) assay to predict the efficacy of PD-L1 second line monotherapy in patients with advanced OAC in a prospective, single-centre, pilot study. Methods: 19 participants received Durvalumab every four weeks. ctDNA was analysed with Guardant 360® CDx at baseline, weeks 4 and 7. Radiological response at week 26 was assessed by RECIST v1.1. Concordance between ctDNA and CT results was pre-defined as either ≥50% increase in ctDNA mean variant allele frequency (VAF) with progressive disease, or ≥50% decrease with radiological response or stable disease. The primary endpoint was to explore whether early changes in ctDNA levels can predict 6-month response to durvalumab by RECIST criteria and considered positive with ≥70% concordance, Tissue biomarkers were assessed with 30X Whole Genome Sequencing. Results: At week four, 6/17 patients (35.3%) have ctDNA VAF changes ≥50%, of which 4/17 (23.5%) show concordance. At week seven, 8/12 (66.7%) have ctDNA changes ≥50%, with concordance in 6/12 participants (50.0%). In post-hoc analyses, 9/12 (75%) of patients show concordance with any ctDNA change at week seven, and the participants with any increase in ctDNA all have progression (5/5 week four, and 7/7 week seven). Conclusions: Although the study’s primary endpoint was not reached, our data supports assessing ctDNA for immunotherapy response prediction. We report that even a modest increase in ctDNA could indicate progressive disease, assisting decision-making to cease ineffective treatments. Further research for the use of ctDNA in OAC is needed. Clinical Trial Information: NCT03653052 (CALIBRATION); drug supplied by AstraZeneca; assay supplied by Guardant.

  • Open Access

    Cell-free DNA size deconvolution resolves nucleosomal origins and reveals tumor-associated fragmentomic alterations

    by Ze Zhou, Wendy N. Cooper, Zhao Cheng, Sara Lightowlers, Charlotte E. Coles, Amit Roshan, Nitzan Rosenfeld, Hui Zhao

    Analysis of cell-free DNA (cfDNA) fragmentomic features holds great promise for minimally invasive cancer diagnostics. Although selectively analyzing short plasma cfDNA enriches tumor-derived DNA (ctDNA), the mechanisms shaping cfDNA size profiles remain incompletely understood. Here, we develop a generalized model of cfDNA fragment length distributions across multiple bodily fluids (saliva, urine, cerebrospinal fluid, lymphatic fluid, and plasma), deconvoluting size profiles into ~10-bp periodic peaks (components), each approximated by a Cauchy–Lorentz distribution. This analytical framework enables investigation of cfDNA fragmentation across diverse pathological states and reveals a 159-bp component that may demarcate intra- and inter-nucleosomal cfDNA. By analyzing plasma DNA from individuals harboring germline TP53 mutations, patients receiving radiotherapy, and liver transplantation recipients, we demonstrate that ctDNA shortening can be distinguished from phagocytosis-associated cfDNA shortening through differences in the amplitude and scale parameters of intra- and inter-nucleosomal components. Moreover, leveraging tumor-related fragmentomic alterations, characterized by increased fragmentation entropy identified through cfDNA size deconvolution, significantly enhances cancer detection.

  • Open Access

    ctDNA monitoring using tumor-informed copy number analysis

    by Ze Zhou, Ros Cutts, Sarah Hrebien, Christina X Zhang, Isaac Garcia‑Murillas, Woody Z Zhang, Alexander M Frankell, Wendy N Cooper, Amit Roshan, Nicholas C Turner, et al.

    Methods to detect circulating tumor DNA (ctDNA) enable minimally invasive responsive monitoring of cancer dynamics. However, sensitive and cost-effective methods are still lacking. Current methods for detecting cancer signals in shallow whole-genome sequencing (sWGS) data from cell-free DNA (cfDNA) via copy number aberration (CNA) analysis typically have a limit of detection of approximately 3% tumor fraction (TF). We developed informCNA, a bioinformatics method that leverages CNA information from sWGS of tumor or pre-treatment plasma samples with high TF as references, enabling ctDNA detection down to 0.2% TF across multiple cancer types. In 177 serial plasma samples from 18 patients with ovarian cancer, informCNA showed high concordance with the standard serum protein marker CA-125 and identified recurrence a median of 3.7 months earlier than CA-125 test. These results demonstrate the potential of personalized CNA analysis through sWGS for estimating ctDNA burden, enabling precise and cost-effective disease monitoring and early detection of relapse.